Management of infections due to KPC-producing Klebsiella pneumoniae by Deresinski, Stanley C & Schirmer, Patricia
Management of infections due to KPC-producing
Klebsiella pneumoniae
Stanley C Deresinski
1,2* and Patricia Schirmer
1,3
Addresses:
1Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, 300 Pasteur Drive, Stanford,
CA 94305-5107, USA;
22900 Whipple Avenue, Suite 115, Redwood City, CA 94062, USA;
3Department of Veterans Affairs, 3801 Miranda Ave
(132), Palo Alto, CA 94304, USA
*Corresponding author: Stanley C Deresinski (polishmd@stanford.edu)
F1000 Medicine Reports 2009, 1:79 (doi:10.3410/M1-79)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/79
Abstract
The emergence of the Klebsiella pneumoniae carbapenemases in K. pneumoniae and other Gram-
negative bacteria, usually on a background of multidrug resistance, has led to difficult therapeutic
choices. Among available antibiotics, tigecycline and the polymyxins are the most frequently active
against these organisms in vitro. Optimal therapy of infections due to these bacteria may involve
maximization of antibiotic dose as well as their use in combination.
Introduction and context
A novel class A serine carbapenemase detected in North
Carolina in 1996 was given the designation KPC-1
because it was first identified in Klebsiella pneumoniae
[1]. Since then, a number of variants of this enzyme
(currently up to KPC-8) have been identified and have
spread globally [2]. The mobile nature of the genetic
element encoding KPC, Tn4401, which is carried on a
plasmid, has contributed to the spread of this enzyme,
which has now been identified in many of the
Enterobacteriaceae as well as in Pseudomonas and
Salmonella [2]. Strain dissemination, however, appears
to be of greater importance than plasmid dissemination
asevidencedbythefactthatalmost70%ofstrainsinaUS
CentersforDiseaseControl andPreventioncollectionare
of a single lineage, sequence type (ST) 258 [3].
KPCs hydrolyze all b-lactam antibiotics and are not
significantly inhibited by clavulanic acid, sulbactam, or
tazobactam [2]. Detection of KPCs in the clinical
laboratory may be difficult and many bacteria producing
thisenzymeappeartobesusceptibletoanti-pseudomonal
carbapenems by routine testing [4]. Resistance to ertape-
nemmaybeamoresensitive(albeitlessspecific)indicator
of the possible presence of KPC than resistance to other
carbapenems. Because of the insensitivity of current
breakpointsindetectingthepresenceofKPC,itissuggested
that isolates of K. pneumoniae with a minimal inhibitory
concentration (MIC) of at least 1 mg/mL to imipenem,
meropenem, or doripenem undergo further testing
designed to detect the presence of carbapenemases,
including KPC [4-6]. The importance of detection resis-
tance in these organisms is evidenced by the fact that the
useofimipenemormeropeneminpatientswithinfections
due to KPC-producing K. pneumoniae that appear to be
susceptible to these carbapenems is associated with
frequent therapeutic failure [7].
KPCs are often accompanied by additional b-lactamases
within individual isolates [4]. A survey of 42 KPC-
producing K. pneumoniae isolates in the Eastern US found
that each isolate carried a mean of 3.5 b-lactamases [4];
one KPC-producing K. pneumoniae isolate has been
reported to contain seven extended spectrum b-
lactamases [8]. K. pneumoniae isolates producing both
KPC-2 and VIM-1 enzymes (the latter of which are class B
metallo-carbapenemases) have been detected in
Greece [9].
Recent advances
KPC-producing bacteria are often resistant to a broad
range of antibiotics beyond the b-lactams. In fact, the
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encoding aminoglycoside-modifying enzymes and some
have also been reported to encode QnrA and QnrB,
resulting in reduced susceptibility to fluoroquinolones
[4,10]. An evaluation of 104 carbapenemase-producing
Enterobacteriaceae, 70% of which produced KPC-2 or
KPC-3, found that the most active agent tested was
tigecycline, to which all isolates were susceptible [11].
Among antibiotics other than b-lactams that were tested,
tigecycline was followed (in decreasing order of suscept-
ibility) by polymyxin B (88% susceptible), amikacin
(73.0%), gentamicin (50.0%), tetracycline (35.6%), and
ciprofloxacin (32.1%). A similar evaluation of 96
carbapenemase-resistant K. pneumoniae from 10 Brook-
lyn hospitals (82% of a single ribotype) also found that
all were susceptible to tigecycline [12]. Ninety-one
percent were considered susceptible to polymyxin B,
66% to doxycycline, 61% to gentamicin, 45% to
amikacin, and 2-7% to chloramphenicol, rifampin,
tobramycin, and ciprofloxacin. Time-kill studies found
that tigecycline was bacteriostatic whereas gentamicin
and polymyxin B were bactericidal. Killing by polymyxin
B was concentration-dependent.
Most published experience of treatment of infection
due to KPC-producing organisms is with tigecycline, a
polymyxin (polymyxin B or colistin), or their combi-
nation, with variable reported outcomes. Monotherapy,
however, may be associated with persistent infection
and the emergence of antibiotic resistance. Recurrence
of an empyema due to a KPC-producing K. pneumoniae
during treatment with tigecycline was associated with
an increase in MIC from 0.75 to 2.0 mg/mL [13].
Elemam and colleagues [14] recently reported two
patients with infections due to K. pneumoniae isolates
resistant to all antibiotics tested, including tigecycline
and polymyxin B, with both isolates having developed
progressive increases in the MIC to polymyxin B during
treatment with this antibiotic. Similarly, of 16 patients
with infection due to carbapenemase-resistant
K. pneumoniae carrying a KPC gene who had persistently
positive cultures, 12 were treated with polymyxin B
alone whereas 4 received this polypeptide antibiotic in
combination with tigecycline for at least a portion of
their therapy [15]. Blood cultures, though initially
positive in only 12, subsequently yielded the organism
in all 16. Marked increases in the polymyxin B MIC were
observed in 3 of the 12 given that antibiotic alone and
in 0 of 4 who also received tigecycline. The develop-
ment of resistance during therapy may be due to the
presence of heteroresistant subpopulations, a phenom-
enon observed with colistin (polymyxin E) in 15 of 16
multidrug-resistant K. pneumoniae isolates considered
susceptible to colistin by MIC testing, a result consistent
with the very high mutant prevention concentration/
MIC ratios observed [16]. Although polymyxin B causes
concentration-dependent killing, this is accompanied
by rapid regrowth of resistant subpopulations with little
or no postantibiotic effect [16], consistent with the
clinical observation of treatment-emergent resistance. It
should be noted that resistance has also been reported
to emerge in Acinetobacter during treatment with
tigecycline [17].
This problem may require optimization of dosage
regimens to overcome some of these characteristics of
polymyxins, combination therapy, or both. Very lim-
ited published clinical experience suggests that combi-
nation therapy may prove to be more successful than
polymyxin monotherapy. Neither antagonism nor
synergy was detected with the combination of tigecy-
cline and polymyxin B tested against three isolates of K.
pneumoniae in vitro [18]. In one series, only 1 of
3 patients with bacteremia due to a KPC-2-producing
K. pneumoniae had a favorable outcome after treatment
with polymyxin B, whereas another patient, treated
with a combination of tetracycline and an aminoglyco-
side, survived [19]. As indicated above, resistance to
polymyxin B occurred in 0 of 4 patients given this
antibiotic in combination with tigecycline, whereas
resistance occurred in 3 of 12 given polymyxin B
monotherapy [15]. Other combinations, such as those
including an active aminoglycoside, may also have
promise: a patient with endocarditis due to KPC-
3-producing K. pneumoniae was successfully treated
with a combination of colistin and gentamicin [20].
Another agent for consideration in combination ther-
apy is rifampin; polymyxin B and rifampin were
synergistic in vitro against 15 of 16 isolates of
carbapenemase-resistant K. pneumoniae [12].
Implications for clinical practice
The optimal therapy for infections due to these multi-
drug-resistant pathogens is not well defined and depends
upon the susceptibilities of individual isolates, and the
choices are often severely limited. The most frequently
active antibiotics in vitro are tigecycline and colistin (or
polymyxin B) and these may often be the only choices
based on susceptibility test results. The pharmaco-
dynamics of the polymyxins remain poorly defined,
and optimal dosing regimens have not yet been
determined [21]. It is possible that doses higher than
those currently approved by the US Food and Drug
Administration may provide improved therapeutic
results. Concerns about toxicity of the polymyxins
(which may have previously been overestimated) have
limited the attempts at significantly increasing the dose
of these agents. In cases of ventilator-associated
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administration of colistin by aerosolization [22].
The currently approved dose of tigecycline results in low
serumandurineconcentrations,raisingconcernaboutthe
efficacy of this agent in the treatment of bacteremia and
urinary tract infections as well as about the emergence of
resistance [17]. Inadequate tissue concentrations may
have accounted for the failure of tigecycline relative to
comparator therapy in the treatment of patients with
ventilator-associated pneumonia due to a variety of
organisms [23]. Cunha [24] has reported administering
tigecycline in a 400 mg loading dose followed by 200 mg
every 24 hours – a dose four times higher than currently
approved – without eliciting nausea or vomiting, frequent
adverse reactions seen with standard dosing regimens.
However, he provides little specific information in regard
to the use of these doses.
Although higher doses of tigecycline or a polymyxin may
be beneficial, lack of knowledge in regard to tolerability
and safety may limit their current acceptance by
clinicians. Combination therapy of serious infections
due to KPC-producing organisms would, however,
appear to be warranted. The combination to be used
depends on the antibiotic susceptibilities of the isolated
pathogen but most often would be tigecycline with a
polymyxin, perhaps at escalated dosages. Limited in vitro
data suggest that co-administration of rifampin may
have a role in such cases. Repeated cultures during
therapy should be performed with monitoring for
emergence of resistance.
The future of therapy for infections caused by multidrug-
resistant aerobic Gram-negative bacilli appears bleak as a
result of the paucity of development of new drugs
targeting these organisms [25]. One potential exception
is the development of b-lactamase inhibitors active
against carbapenemases, such as NXL104, a potent
inhibitor of KPC-2 [26]. It can be hoped that the attitude
of the pharmaceutical industry toward antibiotic devel-
opment will soon change and that additional candidates
will be developed.
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